Skip to main content
SpringerLink
Log in

Sofosbuvir-based regimens good value for HCV genotype 2/3

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2013 US dollars

References

  1. Linas BP, et al. The Cost-Effectiveness of Sofosbuvir-Based Regimens for Treatment of Hepatitis C Virus Genotype 2 or 3 Infection. Annals of Internal Medicine : 30 Mar 2015. Available from: URL: http://doi.org/10.7326/M14-1313.

  2. Etzion O, et al. A Cure for the High Cost of Hepatitis C Virus Treatment. Annals of Internal Medicine : 30 Mar 2015. Available from: URL: http://doi.org/10.7326/M15-0674.

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sofosbuvir-based regimens good value for HCV genotype 2/3. PharmacoEcon Outcomes News 725, 29 (2015). https://doi.org/10.1007/s40274-015-2043-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-015-2043-8

Search

Navigation